← Leaderboards
Irene Sarosiek
Texas Tech University Health Scis Center
$3,156,976
Attributed
$5,901,594
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $530.3K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,901,594 · 1
By mechanism
U01$5,901,594 · 1
Top collaborators
- Richard Warwick Mccallum17 shared
Most similar at Texas Tech University Health Scis Center
Same institution · by research overlap
- Richard Warwick McCallum$2,744,619
Others in their field
Top investigators on “Gastric Emptying”
- Ziad Nahas · Medical University Of South Carolina$22,722,368
- Terry L. Powley · Purdue University West Lafayette$14,132,775
- Randy J. Seeley · University Of Cincinnati$12,543,335
- Michael L Camilleri · Mayo Clinic Coll Of Medicine, Rochester$10,758,941
- Henry P. Parkman · Temple University$8,533,125
- Thomas Lyman Abell · University Of Louisville$7,534,832
Research focus
Gastric EmptyingGastroparesisStomachNational Institute Of Diabetes And Digestive And Kidney DiseasesAbdominal PainRegistriesDiabeticAffectChronicClinical ResearchProtocols DocumentationResponseEtiologyPathogenesisMeetingsDouble-Blind MethodTreatment EfficacyDiagnosisSafetyEnrollmentSymptomsDiagnosticNausea And VomitingDesign
Grant awards (19)
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$350,557
U01 · FY2025 · DK · contact PI
Pediatric Gastroparesis Registry 2 Study (PGpR2) supplement$61,800
U01 · FY2025 · DK · contact PI
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$384,000
U01 · FY2024 · DK
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$61,800
U01 · FY2024 · DK
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$400,000
U01 · FY2023 · DK
Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric Participants with Symptoms of Gastroparesis$61,800
U01 · FY2023 · DK
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$400,000
U01 · FY2022 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$133,333
U01 · FY2021 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$382,355
U01 · FY2020 · DK
Administrative Supplement to Gastroparesis Consortium$147,930
U01 · FY2020 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$386,809
U01 · FY2019 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$374,151
U01 · FY2018 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$378,366
U01 · FY2017 · DK
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$382,500
U01 · FY2016 · DK
Continuation of the NIDDK Gastroparesis Consortium$469,368
U01 · FY2015 · DK
Continuation of the NIDDK Gastroparesis Consortium$466,313
U01 · FY2014 · DK
Continuation of the NIDDK Gastroparesis Consortium$386,847
U01 · FY2013 · DK
Continuation of the NIDDK Gastroparesis Consortium$258,532
U01 · FY2012 · DK
Continuation of the NIDDK Gastroparesis Consortium$415,133
U01 · FY2011 · DK